Xin Xin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin Xin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Guangming Liang
Shenyang Mental Health Center
1 shared publicationGuangyu Zhou
Department of Mood Disorders, Shenyang Mental Health Center, Shenyang, Liaoning, People’s Republic of China
1 shared publication- Guoliang Zheng
Department of Gastric Surgery, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, Shenyang, P. R. China
1 shared publication Lu Ren
Liaoning University of Traditional Chinese Medicine
1 shared publicationXiuzhen Wang
Shenyang Mental Health Center
1 shared publication
Latest Publications
- 4 November 2026
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
Elevated Depressive Symptoms and Reported Mental Health Care Among Middle-Aged and Older Adults in China: A Pooled CHARLS Analysis
Objective: To estimate reported mental health-related diagnosis and treatment frequencies among middle-aged and older adults in China with elevated depressive symptoms, including those with recent general medical contact. Method: Respondent-wave observations were pooled from four Harmonized China Health and Retirement Longitudinal Study (CHARLS) waves (2011-2018) among adults aged 45 or older. Elevated symptoms were defined as a 10-item Center for Epidemiologic Studies Depression Scale score ≥10. Proportions used wave-specific respondent weights; 95% confidence intervals used community-cluster bootstrap resampling. Pooled logistic regression used community-clustered robust standard errors; sensitivity analyses used respondent-clustered and normalized-weight models. Results: Among 67,472 observations from 23,619 individuals, weighted symptom prevalence was 32.4% (95% CI = 31.1%-33.6%). Among symptom-positive observations with outcome data, a doctor diagnosis of emotional, nervous, or psychiatric problems was reported in 3.3% (95% CI = 2.9%-3.7%), and related treatment in 1.3% (95% CI = 1.1%-1.6%). Among 719 symptom-positive observations with reported diagnosis and positive weights, 557 had treatment data; 37.7% (95% CI = 32.1%-43.9%) of these reported treatment. Among symptom-positive observations with recent outpatient or inpatient contact, 4.3% included a reported diagnosis and 1.8% included treatment. Of 5013 respondents with elevated symptoms but no reported diagnosis or treatment in 2011, 76.3% reported elevated symptoms during follow-up; 3.9% later reported diagnosis and 1.3% reported treatment. Conclusions: Reported mental health-related diagnosis and treatment were uncommon among symptom-positive observations, even after recent medical contact. Questionnaire routing and missing treatment data limit interpretation of the apparent gap. Because symptoms and care were self-reported, these estimates should not be interpreted as clinical treatment rates for depressive disorders.
- 4 November 2026
- Published by SAGE Publications in The International Journal of Psychiatry in Medicine
Elevated Depressive Symptoms and Reported Mental Health Care Among Middle-Aged and Older Adults in China: A Pooled CHARLS Analysis
Objective: To estimate reported mental health-related diagnosis and treatment frequencies among middle-aged and older adults in China with elevated depressive symptoms, including those with recent general medical contact. Method: Respondent-wave observations were pooled from four Harmonized China Health and Retirement Longitudinal Study (CHARLS) waves (2011-2018) among adults aged 45 or older. Elevated symptoms were defined as a 10-item Center for Epidemiologic Studies Depression Scale score ≥10. Proportions used wave-specific respondent weights; 95% confidence intervals used community-cluster bootstrap resampling. Pooled logistic regression used community-clustered robust standard errors; sensitivity analyses used respondent-clustered and normalized-weight models. Results: Among 67,472 observations from 23,619 individuals, weighted symptom prevalence was 32.4% (95% CI = 31.1%-33.6%). Among symptom-positive observations with outcome data, a doctor diagnosis of emotional, nervous, or psychiatric problems was reported in 3.3% (95% CI = 2.9%-3.7%), and related treatment in 1.3% (95% CI = 1.1%-1.6%). Among 719 symptom-positive observations with reported diagnosis and positive weights, 557 had treatment data; 37.7% (95% CI = 32.1%-43.9%) of these reported treatment. Among symptom-positive observations with recent outpatient or inpatient contact, 4.3% included a reported diagnosis and 1.8% included treatment. Of 5013 respondents with elevated symptoms but no reported diagnosis or treatment in 2011, 76.3% reported elevated symptoms during follow-up; 3.9% later reported diagnosis and 1.3% reported treatment. Conclusions: Reported mental health-related diagnosis and treatment were uncommon among symptom-positive observations, even after recent medical contact. Questionnaire routing and missing treatment data limit interpretation of the apparent gap. Because symptoms and care were self-reported, these estimates should not be interpreted as clinical treatment rates for depressive disorders.
- 29 September 2026
- Published by Elsevier in Nutrition Research
- Vol. 155, 132-141
Selected red blood cell folate measures are associated with lower odds of insufficient sleep in United States adults
- 29 September 2026
- Published by Elsevier in Nutrition Research
- Vol. 155, 132-141
Selected red blood cell folate measures are associated with lower odds of insufficient sleep in United States adults
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-10
Serum Lithium Monitoring, Short-Term Outcomes, and Treatment Barriers in Bipolar Disorder: A Real-World Study
Purpose: To characterize serum lithium monitoring, clinician-recorded short-term outcomes, and treatment barriers in a clinically selected outpatient cohort of patients with bipolar disorder that was enriched for suicide risk. Patients and Methods: We retrospectively reviewed consecutive routine-care records from a specialist mood-disorders clinic between January 2024 and March 2025. The monitoring dataset comprised 188 patients and 562 valid serum lithium measurements. The outcome dataset comprised 124 patient-level records from initial or follow-up encounters, and a separate implementation dataset contained 13 patients with documented discontinuation or non-initiation. The serum lithium value closest to the clinical outcome assessment was used in exploratory analyses. Results: Among monitored patients, 124/188 (66.0%) had at least two measurements. Median serum lithium concentration was 0.62 mmol/L (interquartile range 0.50– 0.84), and 18/562 measurements (3.2%) were > 1.2 mmol/L. Clinician-recorded remission was documented in 72/124 outcome records (58.1%) and any improvement in 114/124 (91.9%). Any improvement was 90.0%, 96.1%, and 81.5% in the < 0.4, 0.4-< 0.8, and ≥ 0.8 mmol/L groups, respectively (exploratory unadjusted P=0.053). Remission did not differ across groups (P=0.952), and the continuous serum lithium value was not associated with remission (odds ratio per 0.1 mmol/L, 1.01; 95% confidence interval 0.86– 1.18). Documented barriers included adverse effects, testing or logistical burden, toxicity concerns, and poor palatability. Conclusion: A single routine-care serum lithium concentration recorded near a clinical assessment was not associated with clinician-recorded remission. The analysis did not evaluate longitudinal exposure or confirmed steady-state trough concentrations, and improvement during comprehensive care cannot be attributed to lithium alone. These findings support an integrated lithium-care pathway that combines interpretable monitoring, accessible testing, early management of adverse effects, clear toxicity education, and suicide-specific safety planning.
- 1 August 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-10
Open AccessSerum Lithium Monitoring, Short-Term Outcomes, and Treatment Barriers in Bipolar Disorder: A Real-World Study
Purpose: To characterize serum lithium monitoring, clinician-recorded short-term outcomes, and treatment barriers in a clinically selected outpatient cohort of patients with bipolar disorder that was enriched for suicide risk. Patients and Methods: We retrospectively reviewed consecutive routine-care records from a specialist mood-disorders clinic between January 2024 and March 2025. The monitoring dataset comprised 188 patients and 562 valid serum lithium measurements. The outcome dataset comprised 124 patient-level records from initial or follow-up encounters, and a separate implementation dataset contained 13 patients with documented discontinuation or non-initiation. The serum lithium value closest to the clinical outcome assessment was used in exploratory analyses. Results: Among monitored patients, 124/188 (66.0%) had at least two measurements. Median serum lithium concentration was 0.62 mmol/L (interquartile range 0.50– 0.84), and 18/562 measurements (3.2%) were > 1.2 mmol/L. Clinician-recorded remission was documented in 72/124 outcome records (58.1%) and any improvement in 114/124 (91.9%). Any improvement was 90.0%, 96.1%, and 81.5% in the < 0.4, 0.4-< 0.8, and ≥ 0.8 mmol/L groups, respectively (exploratory unadjusted P=0.053). Remission did not differ across groups (P=0.952), and the continuous serum lithium value was not associated with remission (odds ratio per 0.1 mmol/L, 1.01; 95% confidence interval 0.86– 1.18). Documented barriers included adverse effects, testing or logistical burden, toxicity concerns, and poor palatability. Conclusion: A single routine-care serum lithium concentration recorded near a clinical assessment was not associated with clinician-recorded remission. The analysis did not evaluate longitudinal exposure or confirmed steady-state trough concentrations, and improvement during comprehensive care cannot be attributed to lithium alone. These findings support an integrated lithium-care pathway that combines interpretable monitoring, accessible testing, early management of adverse effects, clear toxicity education, and suicide-specific safety planning.